large b cell lymphoma |The study gives promising results to treat lymphoma patients with immune cell treatment

The study gives promising results to treat lymphoma patients with immune cell treatment



Lymphoma is the most common blood cancer. The disease occurs when lymphocytes called immune cells multiply uncontrollably. Cancerous lymphocytes can move throughout the fuselage and form lymph node tumors. The fuselage has two types of lymphocytes that can develop in lymphoma-B cells and T cells. B lymphocyte lymphomas account for 85 percent of all non-Hodgkin lymphomas and 30 percent of these patients are diagnosed with large diffuse B lymphocyte lymphoma.

Large Diffuse B lymphocyte lymphoma is an aggressive B lymphocyte cancer that can quickly spread throughout the fuselage. This means that it requires immediate settlement request including drug therapy, radiation therapy and possibly a stem cell transplant. However, half of all diffuse the large B lymphocyte as patients relapse after normal treatments and become insensitive to chemotherapy claims (refractory disease).

Moffitt Cancer Center Doctor researchers are working to carry immune cell treatments diffuse patients from refractory to large B lymphocyte lymphoma. Promising results from Phase 1 part of the ZUMA-1 study, which uses the chimeric antigen receptor (RAC) modified T cells to treat B-cell lymphoma patients, were published in the January issue of treatment Molecular, the official Journal of the American Gene Society and Cell therapy.

The Ciloleucel of Axicabtagene (KTE-C19), developed by the Kite Pharma, is a chimeric autologue T lymphocyte (CAR) treatment of antigen receptor. In the trolley treatment using Axicabtagene ciloleucel (KTE-C19), T cells are isolated in a patient's blood and designed at the central Kite Pharma industrial facility to target the CD19 protein which is found on Lymphoma cells. The retargeted T cells are then re-infused into the same patient. The T cells of the Axicabtagene ciloleucel (KTE-C19) can identify lymphoma cancer cells that express CD19 and target them for destruction.

The objective of Phase 1 part of the ZUMA-1 study was to determine the safety of Axicabtagene ciloleucel (KTE-C19) as assessed by the frequency of dose-limiting toxicity in patients with large diffuse B lymphocyte lymphoma that were Refractory to previous treatment that included anti-CD20 treatment and a anthracycline-containing diet. The study included patients who had the highly refractory disease, presenting two to four previous claims.

This is the first multicentric study of a trolley treatment that was produced manufactured at a centrally located facility. Moffitt's research team, completed by Frederick L. Locke, M.D., records that the manufacturing process for the Axicabtagene ciloleucel (KTE-C19) was successful for all patients and was filled within approximately two weeks.

After successful manufacture of Axicabtagene Ciloleucel (KTE-C19), cells were re-shipped to Moffitt and other participating sites where patients were treated with revision chemotherapy followed by infusion with the Ciloleucel Axicabtagene (KTE-C19). The Locke team found that the ciloleucel of Axicabtagene (KTE-C19) trained planned but manageable, toxicity over a median additional period of nine months. Of the 7 patients treated with the ciloleucel of Axicabtagene (KTE-C19), 1 patient noticed dose-limiting the toxicity of the syndrome and the neurotoxicity of cytokine release.

The Ciloleucel of Axicabtagene (KTE-C19) resulted in promising clinical activity. The general response rate was 71 per cent (5 of 7 patients) and 4 patients developed a rapid full response within 1 month of claim. The claim was also sustainable with 43 percent, or remain 3 patients in full remission after one year.

The general and complete response rate to this small group of patients is remarkable, as the complete response rate expected for such patients is 8 per cent with conventional chemotherapy. This is really an exciting time for the oncology community and our patients. The designed immune cell treatments are a phase closer to widespread availability. Said Locke, research director for the Moffitt immune cell treatment Clinical Test group.

Promising Phase 1 results for initiation of the pivotalement Phase 2 parts of the ZUMA-1 study in aggressive non-Hodgkin's lymphoma that includes large diffuse B lymphocyte lymphoma, primary mediastinal b lymphocyte lymphoma, and Follicular lymphoma transformed.

Source:
: H. Centre for Cancer Control and Research Institute of Lee Moffitt